Article By:
ChinaBio® Today
Saturday, October 14, 2023 12:59 PM EDT
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with potential value of more than $1 billion.